Alpine Immune Sciences In... (ALPN)
Alpine Immune Sciences Statistics
Share Statistics
Alpine Immune Sciences has 68.6M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 68.6M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 47.88M |
| Failed to Deliver (FTD) Shares | 7 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -29.61 and the forward PE ratio is null. Alpine Immune Sciences's PEG ratio is 0.47.
| PE Ratio | -29.61 |
| Forward PE | n/a |
| PS Ratio | 16.19 |
| Forward PS | null |
| PB Ratio | 2.91 |
| P/FCF Ratio | -11.99 |
| PEG Ratio | 0.47 |
Enterprise Valuation
Alpine Immune Sciences has an Enterprise Value (EV) of 919M.
| EV / Sales | 15.61 |
| EV / EBITDA | -21.04 |
| EV / EBIT | -11.63 |
| EV / FCF | -11.56 |
Financial Position
The company has a current ratio of 7.86, with a Debt / Equity ratio of 0.03.
| Current Ratio | 7.86 |
| Quick Ratio | 7.87 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | -0.23 |
| Debt / FCF | -0.12 |
| Interest Coverage | -451.53 |
Financial Efficiency
Return on Equity is -9.81% and Return on Invested Capital is -13.14%.
| Return on Equity | -9.81% |
| Return on Assets | -8.47% |
| Return on Invested Capital | -13.14% |
| Revenue Per Employee | $414.62K |
| Profits Per Employee | $-226.65K |
| Employee Count | 142 |
| Asset Turnover | 0.15 |
| Inventory Turnover | -484.46 |
Taxes
| Income Tax | 103K |
| Effective Tax Rate | -0.32% |
Stock Price Statistics
The stock price has increased by 0.6% in the last 52 weeks. The beta is 0.97, so Alpine Immune Sciences's price volatility has been higher than the market average.
| Beta | 0.97 |
| 52-Week Price Change | 0.6% |
| 50-Day Moving Average | 53.07 |
| 200-Day Moving Average | 26.53 |
| Relative Strength Index (RSI) | 83.31 |
| Average Volume (20 Days) | 2.37M |
Income Statement
In the last 12 months, Alpine Immune Sciences had revenue of 58.88M and earned -32.18M in profits. Earnings per share was -0.64.
| Revenue | 58.88M |
| Gross Profit | -22.03M |
| Operating Income | -44.25M |
| Net Income | -32.18M |
| EBITDA | -43.67M |
| EBIT | -31.98M |
| Earnings Per Share (EPS) | -0.64 |
Balance Sheet
The company has 43.92M in cash and 9.91M in debt, giving a net cash position of 34.01M.
| Cash & Cash Equivalents | 43.92M |
| Total Debt | 9.91M |
| Net Cash | 34.01M |
| Retained Earnings | -256.14M |
| Total Assets | 373.65M |
| Working Capital | 276.01M |
Cash Flow
In the last 12 months, operating cash flow was -79.01M and capital expenditures -487K, giving a free cash flow of -79.5M.
| Operating Cash Flow | -79.01M |
| Capital Expenditures | -487K |
| Free Cash Flow | -79.5M |
| FCF Per Share | -1.59 |
Margins
Gross margin is -37.41%, with operating and profit margins of -75.16% and -54.66%.
| Gross Margin | -37.41% |
| Operating Margin | -75.16% |
| Pretax Margin | -54.49% |
| Profit Margin | -54.66% |
| EBITDA Margin | -74.18% |
| EBIT Margin | -75.16% |
| FCF Margin | -135.03% |
Dividends & Yields
ALPN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -3.38% |
| FCF Yield | -8.34% |
Analyst Forecast
Currently there are no analyst rating for ALPN.
| Price Target | $65 |
| Price Target Difference | 0% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Jul 25, 2017. It was a backward split with a ratio of 1:4.
| Last Split Date | Jul 25, 2017 |
| Split Type | backward |
| Split Ratio | 1:4 |
Scores
| Altman Z-Score | 64.92 |
| Piotroski F-Score | 3 |